Ximelagatran data fail to impress FDA.
Thompson
Cheryl A
CA
D026683:Advisory Committees; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy; D001384:Azetidines / Q000009:adverse effects* / Q000627:therapeutic use; D001596:Benzylamines; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D017277:Drug Approval; D004617:Embolism / Q000517:prevention & control; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D014481:United States; D014486:United States Food and Drug Administration; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; C426686:ximelagatran